Figure 3
(a) Individual Aβ-PET estimates from baseline (12 months) to termination (18 months). Longitudinal courses of SUVRCTX/CBL for each mouse are depicted by individual lines. Symbols and lines for representative mice #5 and #6 (TG-GSM, red), as well as mouse #21 (TG-VEH, green) are accentuated. (b) Axial slices of Aβ-PET images from mice #5, #6 and #21 at each study point superimposed on an MRI atlas. (c) Absolute SUVRCTX/CBL values for each of the three PET scanning times are shown for TG-GSM (red) and TG-VEH (green) mice. The thick line marks the mean value, whereas the filled area indicates the s.d. for all mice. *indicates statistically significant at P<0.05. (d) Percentage increase of follow-up and termination SUVRCTX/CBL relative to individual baseline values for TG-GSM (red) and TG-VEH (green) mice. The thick line marks the mean value, whereas the filled area indicates the s.d. of all mice. ***indicates statistically significant at P<0.001. (e) Response prediction by means of Aβ-PET. The percentage increase from baseline to termination SUVRCTX/CBL is depicted as a function of the individual baseline value. For the TG-GSM, a low baseline value predicted a lesser increase in amyloidosis during treatment, whereas mice with a high baseline value had a high increase despite treatment. For the TG-VEH, there was a remarkable increase in SUVRCTX/CBL, which was not a function of the individual baseline value. The correlations (r) between the percentage increase and the baseline value are indicated.
